EVLO (Evelo Biosciences) Liabilities-to-Assets : 2.30 (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Evelo Biosciences Liabilities-to-Assets?

Evelo Biosciences EVLO -99.00% Liabilities-to-Assets is 2.30 as of Sep. 2023.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Evelo Biosciences's Total Liabilities for the quarter that ended in Sep. 2023 was $47.33 Mil. Evelo Biosciences's Total Assets for the quarter that ended in Sep. 2023 was $20.63 Mil. Therefore, Evelo Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 was 2.30.

Evelo Biosciences  (OTCPK:EVLO) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Evelo Biosciences Liabilities-to-Assets Related Terms

Evelo Biosciences Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences Liabilities-to-Assets Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Liabilities-to-Assets
Get a 7-Day Free Trial 0.14 0.34 0.66 0.90 1.08

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 1.08 1.65 3.22 2.30

EVLO vs IMNN, EDSA, TMBR: Liabilities-to-Assets Comparison

For the Biotechnology subindustry, Evelo Biosciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evelo Biosciences Liabilities-to-Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's Liabilities-to-Assets falls into.


Evelo Biosciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Evelo Biosciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Liabilities-to-Assets (A: Dec. 2022 )=Total Liabilities/Total Assets
=69.433/64.441
=1.08

Evelo Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 is calculated as

Liabilities-to-Assets (Q: Sep. 2023 )=Total Liabilities/Total Assets
=47.334/20.627
=2.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 2.30 mean?
Evelo Biosciences (EVLO) has a Liabilities-to-Assets of 2.30 as of Sep. 2023. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Evelo Biosciences and its competitors.
Is Evelo Biosciences' Liabilities-to-Assets too high?
Evelo Biosciences' current Liabilities-to-Assets is 2.30.
How does Evelo Biosciences' Liabilities-to-Assets compare to IMNN and EDSA?
Evelo Biosciences' Liabilities-to-Assets of 2.30 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Evelo Biosciences and its competitors. Evelo Biosciences's current Liabilities-to-Assets is 2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current Liabilities-to-Assets of 2.30. The current Liabilities-to-Assets is 2.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current Liabilities-to-Assets is 2.30 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.